Drug intelligence / Profile preview

IMT-PSK3

Development stage: Preclinical
Lead developer: ImunoTera

Overview

IMT-PSK3 is an early-stage therapeutic candidate being developed by the Brazilian biotechnology company ImunoTera for the treatment of prostate cancer. Currently in the preclinical phase, the specific molecular target and therapeutic modality (such as recombinant protein or DNA vaccine) have not yet been publicly disclosed by the developer. ImunoTera's broader research focus involves leveraging proprietary platforms to create immunotherapies that stimulate robust T-cell responses against tumor-specific antigens.

Beyond the preview

Go deeper on IMT-PSK3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMT-PSK3.

Explore the full profile